| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Detected and Quantified |
|---|
| Creation Date | 2005-11-16 15:48:42 UTC |
|---|
| Update Date | 2025-05-29 18:10:23 UTC |
|---|
| HMDB ID | HMDB0000094 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Citric acid |
|---|
| Description | Citric acid (citrate) is a tricarboxylic acid, an organic acid with three carboxylate groups. Citrate is an intermediate in the TCA cycle (also known as the Tricarboxylic Acid cycle, the Citric Acid cycle or Krebs cycle). The TCA cycle is a central metabolic pathway for all animals, plants, and bacteria. As a result, citrate is found in all living organisms, from bacteria to plants to animals. In the TCA cycle, the enzyme citrate synthase catalyzes the condensation of oxaloacetate with acetyl CoA to form citrate. Citrate then acts as the substrate for the enzyme known as aconitase and is then converted into aconitic acid. The TCA cycle ends with regeneration of oxaloacetate. This series of chemical reactions in the TCA cycle is the source of two-thirds of the food-derived energy in higher organisms. Citrate can be transported out of the mitochondria and into the cytoplasm, then broken down into acetyl-CoA for fatty acid synthesis, and into oxaloacetate. Citrate is a positive modulator of this conversion, and allosterically regulates the enzyme acetyl-CoA carboxylase, which is the regulating enzyme in the conversion of acetyl-CoA into malonyl-CoA (the commitment step in fatty acid synthesis). In short, citrate is transported into the cytoplasm, converted into acetyl CoA, which is then converted into malonyl CoA by acetyl CoA carboxylase, which is allosterically modulated by citrate. In mammals and other vertebrates, Citrate is a vital component of bone, helping to regulate the size of apatite crystals (PMID: 21127269 ). Citric acid is found in citrus fruits, most concentrated in lemons and limes, where it can comprise as much as 8% of the dry weight of the fruit. Citric acid is a natural preservative and is also used to add an acidic (sour) taste to foods and carbonated drinks. Because it is one of the stronger edible acids, the dominant use of citric acid is as a flavoring and preservative in food and beverages, especially soft drinks and candies. Citric acid is an excellent chelating agent, binding metals by making them soluble. It is used to remove and discourage the buildup of limescale from boilers and evaporators. It can be used to treat water, which makes it useful in improving the effectiveness of soaps and laundry detergents. The salts of citric acid (citrates) can be used as anticoagulants due to their calcium chelating ability. Intolerance to citric acid in the diet is known to exist. Little information is available as the condition appears to be rare, but like other types of food intolerance it is often described as a "pseudo-allergic" reaction. |
|---|
| Structure | OC(=O)CC(O)(CC(O)=O)C(O)=O InChI=1S/C6H8O7/c7-3(8)1-6(13,5(11)12)2-4(9)10/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12) |
|---|
| Synonyms | | Value | Source |
|---|
| 2-Hydroxy-1,2,3-propanetricarboxylic acid | ChEBI | | 2-Hydroxytricarballylic acid | ChEBI | | 3-Carboxy-3-hydroxypentane-1,5-dioic acid | ChEBI | | Citronensaeure | ChEBI | | e330 | ChEBI | | H3Cit | ChEBI | | Anhydrous citric acid | Kegg | | Citric acid anhydrous | Kegg | | 2-Hydroxy-1,2,3-propanetricarboxylate | Generator | | 2-Hydroxytricarballylate | Generator | | 3-Carboxy-3-hydroxypentane-1,5-dioate | Generator | | Anhydrous citrate | Generator | | Citrate anhydrous | Generator | | Citrate | Generator | | Aciletten | HMDB | | beta-Hydroxytricarballylate | HMDB | | beta-Hydroxytricarballylic acid | HMDB | | Chemfill | HMDB | | Citraclean | HMDB | | Citretten | HMDB | | Citro | HMDB | | e 330 | HMDB | | Hydrocerol a | HMDB | | Kyselina citronova | HMDB | | Suby g | HMDB | | Uro-trainer | HMDB | | Acid monohydrate, citric | HMDB | | Monohydrate, citric acid | HMDB | | Citric acid, anhydrous | HMDB | | Citric acid monohydrate | HMDB | | Uralyt u | HMDB |
|
|---|
| Chemical Formula | C6H8O7 |
|---|
| Average Molecular Weight | 192.1235 |
|---|
| Monoisotopic Molecular Weight | 192.02700261 |
|---|
| IUPAC Name | 2-hydroxypropane-1,2,3-tricarboxylic acid |
|---|
| Traditional Name | citric acid |
|---|
| CAS Registry Number | 77-92-9 |
|---|
| SMILES | OC(=O)CC(O)(CC(O)=O)C(O)=O |
|---|
| InChI Identifier | InChI=1S/C6H8O7/c7-3(8)1-6(13,5(11)12)2-4(9)10/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12) |
|---|
| InChI Key | KRKNYBCHXYNGOX-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as tricarboxylic acids and derivatives. These are carboxylic acids containing exactly three carboxyl groups. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organic acids and derivatives |
|---|
| Class | Carboxylic acids and derivatives |
|---|
| Sub Class | Tricarboxylic acids and derivatives |
|---|
| Direct Parent | Tricarboxylic acids and derivatives |
|---|
| Alternative Parents | |
|---|
| Substituents | - Tricarboxylic acid or derivatives
- Hydroxy acid
- Alpha-hydroxy acid
- Tertiary alcohol
- Carboxylic acid
- Organic oxygen compound
- Organic oxide
- Hydrocarbon derivative
- Organooxygen compound
- Carbonyl group
- Alcohol
- Aliphatic acyclic compound
|
|---|
| Molecular Framework | Aliphatic acyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | |
|---|
| Disposition | |
|---|
| Process | |
|---|
| Role | |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 153 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 592 mg/mL | Not Available | | LogP | -1.64 | AVDEEF,A (1997) |
|
|---|
| Experimental Chromatographic Properties | Experimental Collision Cross Sections |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 1.57 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 10.2385 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 6.76 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 326.2 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 634.6 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 341.4 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 39.4 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 192.0 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 74.0 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 269.9 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 251.0 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 684.3 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 622.6 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 44.3 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 893.8 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 208.1 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 287.0 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 831.4 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 277.5 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 605.1 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Citric acid,1TMS,isomer #1 | C[Si](C)(C)OC(=O)CC(O)(CC(=O)O)C(=O)O | 1684.6 | Semi standard non polar | 33892256 | | Citric acid,1TMS,isomer #2 | C[Si](C)(C)OC(CC(=O)O)(CC(=O)O)C(=O)O | 1739.7 | Semi standard non polar | 33892256 | | Citric acid,1TMS,isomer #3 | C[Si](C)(C)OC(=O)C(O)(CC(=O)O)CC(=O)O | 1653.7 | Semi standard non polar | 33892256 | | Citric acid,2TMS,isomer #1 | C[Si](C)(C)OC(=O)CC(CC(=O)O)(O[Si](C)(C)C)C(=O)O | 1750.6 | Semi standard non polar | 33892256 | | Citric acid,2TMS,isomer #2 | C[Si](C)(C)OC(=O)CC(O)(CC(=O)O[Si](C)(C)C)C(=O)O | 1738.2 | Semi standard non polar | 33892256 | | Citric acid,2TMS,isomer #3 | C[Si](C)(C)OC(=O)CC(O)(CC(=O)O)C(=O)O[Si](C)(C)C | 1706.7 | Semi standard non polar | 33892256 | | Citric acid,2TMS,isomer #4 | C[Si](C)(C)OC(=O)C(CC(=O)O)(CC(=O)O)O[Si](C)(C)C | 1747.3 | Semi standard non polar | 33892256 | | Citric acid,3TMS,isomer #1 | C[Si](C)(C)OC(=O)CC(CC(=O)O[Si](C)(C)C)(O[Si](C)(C)C)C(=O)O | 1753.3 | Semi standard non polar | 33892256 | | Citric acid,3TMS,isomer #2 | C[Si](C)(C)OC(=O)CC(CC(=O)O)(O[Si](C)(C)C)C(=O)O[Si](C)(C)C | 1772.3 | Semi standard non polar | 33892256 | | Citric acid,3TMS,isomer #3 | C[Si](C)(C)OC(=O)CC(O)(CC(=O)O[Si](C)(C)C)C(=O)O[Si](C)(C)C | 1750.8 | Semi standard non polar | 33892256 | | Citric acid,4TMS,isomer #1 | C[Si](C)(C)OC(=O)CC(CC(=O)O[Si](C)(C)C)(O[Si](C)(C)C)C(=O)O[Si](C)(C)C | 1834.5 | Semi standard non polar | 33892256 | | Citric acid,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC(=O)CC(O)(CC(=O)O)C(=O)O | 1956.9 | Semi standard non polar | 33892256 | | Citric acid,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OC(CC(=O)O)(CC(=O)O)C(=O)O | 1981.1 | Semi standard non polar | 33892256 | | Citric acid,1TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)OC(=O)C(O)(CC(=O)O)CC(=O)O | 1950.5 | Semi standard non polar | 33892256 | | Citric acid,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC(=O)CC(CC(=O)O)(O[Si](C)(C)C(C)(C)C)C(=O)O | 2198.3 | Semi standard non polar | 33892256 | | Citric acid,2TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OC(=O)CC(O)(CC(=O)O[Si](C)(C)C(C)(C)C)C(=O)O | 2219.2 | Semi standard non polar | 33892256 | | Citric acid,2TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)OC(=O)CC(O)(CC(=O)O)C(=O)O[Si](C)(C)C(C)(C)C | 2221.7 | Semi standard non polar | 33892256 | | Citric acid,2TBDMS,isomer #4 | CC(C)(C)[Si](C)(C)OC(=O)C(CC(=O)O)(CC(=O)O)O[Si](C)(C)C(C)(C)C | 2208.7 | Semi standard non polar | 33892256 | | Citric acid,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC(=O)CC(CC(=O)O[Si](C)(C)C(C)(C)C)(O[Si](C)(C)C(C)(C)C)C(=O)O | 2444.2 | Semi standard non polar | 33892256 | | Citric acid,3TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OC(=O)CC(CC(=O)O)(O[Si](C)(C)C(C)(C)C)C(=O)O[Si](C)(C)C(C)(C)C | 2439.1 | Semi standard non polar | 33892256 | | Citric acid,3TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)OC(=O)CC(O)(CC(=O)O[Si](C)(C)C(C)(C)C)C(=O)O[Si](C)(C)C(C)(C)C | 2420.7 | Semi standard non polar | 33892256 | | Citric acid,4TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC(=O)CC(CC(=O)O[Si](C)(C)C(C)(C)C)(O[Si](C)(C)C(C)(C)C)C(=O)O[Si](C)(C)C(C)(C)C | 2635.9 | Semi standard non polar | 33892256 |
|
|---|
| Spectra |
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental GC-MS | GC-MS Spectrum - Citric acid GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (4 TMS) | splash10-0002-0941000000-c310fda0e6a19bf6ae40 | 2014-06-16 | HMDB team, MONA, MassBank | View Spectrum | | Experimental GC-MS | GC-MS Spectrum - Citric acid GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (4 TMS) | splash10-0002-0941000000-f1dfda3e9abc7cfb6b2a | 2014-06-16 | HMDB team, MONA, MassBank | View Spectrum | | Experimental GC-MS | GC-MS Spectrum - Citric acid GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (4 TMS) | splash10-006t-0952000000-ba3a1a80815f65afd05c | 2014-06-16 | HMDB team, MONA, MassBank | View Spectrum | | Experimental GC-MS | GC-MS Spectrum - Citric acid GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (Non-derivatized) | splash10-0002-0951000000-48857e9baebe16d9fc8d | 2014-06-16 | HMDB team, MONA, MassBank | View Spectrum | | Experimental GC-MS | GC-MS Spectrum - Citric acid GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (4 TMS) | splash10-00di-9531000000-b6fd7d038634694f0873 | 2014-06-16 | HMDB team, MONA, MassBank | View Spectrum | | Experimental GC-MS | GC-MS Spectrum - Citric acid GC-MS (4 TMS) | splash10-00di-0593000000-b193bbba8c0cefdfe42a | 2014-06-16 | HMDB team, MONA, MassBank | View Spectrum | | Experimental GC-MS | GC-MS Spectrum - Citric acid GC-EI-TOF (Non-derivatized) | splash10-0002-0941000000-c310fda0e6a19bf6ae40 | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | | Experimental GC-MS | GC-MS Spectrum - Citric acid GC-EI-TOF (Non-derivatized) | splash10-0002-0941000000-f1dfda3e9abc7cfb6b2a | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | | Experimental GC-MS | GC-MS Spectrum - Citric acid GC-EI-TOF (Non-derivatized) | splash10-006t-0952000000-ba3a1a80815f65afd05c | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | | Experimental GC-MS | GC-MS Spectrum - Citric acid GC-EI-TOF (Non-derivatized) | splash10-0002-0951000000-48857e9baebe16d9fc8d | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | | Experimental GC-MS | GC-MS Spectrum - Citric acid GC-EI-TOF (Non-derivatized) | splash10-00di-9531000000-b6fd7d038634694f0873 | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | | Experimental GC-MS | GC-MS Spectrum - Citric acid GC-MS (Non-derivatized) | splash10-00di-0593000000-b193bbba8c0cefdfe42a | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | | Experimental GC-MS | GC-MS Spectrum - Citric acid GC-EI-TOF (Non-derivatized) | splash10-0002-0941000000-573230e47a4efb1e36a5 | 2017-09-12 | HMDB team, MONA, MassBank | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Citric acid GC-MS (Non-derivatized) - 70eV, Positive | splash10-002k-6900000000-d1a61a52f6efdec3101a | 2016-09-22 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Citric acid GC-MS (4 TMS) - 70eV, Positive | splash10-02ib-6019300000-6d5ebea10441c6d4149a | 2017-10-06 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Citric acid GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Citric acid GC-MS (TMS_1_1) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Citric acid GC-MS (TMS_1_2) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Citric acid GC-MS (TMS_1_3) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Citric acid GC-MS (TMS_2_1) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Citric acid GC-MS (TMS_2_2) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Citric acid GC-MS (TMS_2_3) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Citric acid GC-MS (TMS_2_4) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Citric acid GC-MS (TMS_3_1) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Citric acid GC-MS (TMS_3_2) - 70eV, Positive | Not Available | 2021-11-05 | Wishart Lab | View Spectrum | | MS | Mass Spectrum (Electron Ionization) | splash10-002f-9400000000-fb757b614278bb898b54 | 2014-09-20 | Not Available | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental LC-MS/MS | LC-MS/MS Spectrum - Citric acid Quattro_QQQ 10V, Negative-QTOF (Annotated) | splash10-03di-2900000000-956001b034bbc0b7da96 | 2012-07-24 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Citric acid Quattro_QQQ 25V, Negative-QTOF (Annotated) | splash10-000l-9100000000-55e34e2c1616942fd4f2 | 2012-07-24 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Citric acid Quattro_QQQ 40V, Negative-QTOF (Annotated) | splash10-000f-9000000000-7b8be3e90a4daf85f04a | 2012-07-24 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Citric acid LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Negative-QTOF | splash10-0006-0911200000-af80d22f720facc4813a | 2012-08-31 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Citric acid LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Negative-QTOF | splash10-014i-9000000000-6f4fedbb19821898fb22 | 2012-08-31 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Citric acid LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Negative-QTOF | splash10-03di-0900000000-8eff68ab89f7ce2262be | 2012-08-31 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Citric acid LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Negative-QTOF | splash10-0fsi-0019300000-b370c4c3dd656c8eb729 | 2012-08-31 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Citric acid LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Negative-QTOF | splash10-0006-0912100000-05e8ceb6dd97f7b9af98 | 2012-08-31 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Citric acid LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Negative-QTOF | splash10-014i-9000000000-e4b67745443c48a63bd6 | 2012-08-31 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Citric acid LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Negative-QTOF | splash10-03di-0900000000-92536abec982e0a653a0 | 2012-08-31 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Citric acid LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , Negative-QTOF | splash10-03di-0190000000-35772df08490f451d828 | 2012-08-31 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Citric acid LC-ESI-QQ (API3000, Applied Biosystems) 10V, Negative-QTOF | splash10-0006-0900000000-35856cc258368d13e1ff | 2012-08-31 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Citric acid LC-ESI-QQ (API3000, Applied Biosystems) 20V, Negative-QTOF | splash10-03di-3900000000-7170fdcb9749e6d6c2fb | 2012-08-31 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Citric acid LC-ESI-QQ (API3000, Applied Biosystems) 30V, Negative-QTOF | splash10-01p9-9500000000-9a502981b0a9e1ea35ad | 2012-08-31 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Citric acid LC-ESI-QQ (API3000, Applied Biosystems) 40V, Negative-QTOF | splash10-000i-9100000000-ed0c86b90e1f4966d025 | 2012-08-31 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Citric acid LC-ESI-QQ (API3000, Applied Biosystems) 50V, Negative-QTOF | splash10-0a4r-9000000000-b8a975c2d639d8c91afb | 2012-08-31 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Citric acid LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) , Negative-QTOF | splash10-03di-2900000000-30970a4250098e148658 | 2012-08-31 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Citric acid LC-ESI-QQ , negative-QTOF | splash10-0006-0900000000-a587dddf188152c5d7b0 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Citric acid LC-ESI-QQ , negative-QTOF | splash10-03di-3900000000-7170fdcb9749e6d6c2fb | 2017-09-14 | HMDB team, MONA | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Citric acid 10V, Positive-QTOF | splash10-0037-0900000000-06dccacb53e75edc8b8d | 2016-09-12 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Citric acid 20V, Positive-QTOF | splash10-02cu-5900000000-bfea9d561968b2670b13 | 2016-09-12 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Citric acid 40V, Positive-QTOF | splash10-002r-7900000000-b1d32e4661447b09a017 | 2016-09-12 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Citric acid 10V, Negative-QTOF | splash10-0005-1900000000-d074598ec2180f8b600c | 2016-09-12 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Citric acid 20V, Negative-QTOF | splash10-0k92-3900000000-9917f196271a495d3d1e | 2016-09-12 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Citric acid 40V, Negative-QTOF | splash10-0pb9-9600000000-513b016c7c951d1e0b12 | 2016-09-12 | Wishart Lab | View Spectrum |
NMR Spectra| Spectrum Type | Description | Deposition Date | Source | View |
|---|
| Experimental 1D NMR | 1H NMR Spectrum (1D, 500 MHz, H2O, experimental) | 2012-12-04 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | | Experimental 2D NMR | [1H, 13C]-HSQC NMR Spectrum (2D, 600 MHz, H2O, experimental) | 2012-12-04 | Wishart Lab | View Spectrum |
IR Spectra| Spectrum Type | Description | Deposition Date | Source | View |
|---|
| Predicted IR Spectrum | IR Ion Spectrum (Predicted IRIS Spectrum, Adduct: [M-H]-) | 2023-02-03 | FELIX lab | View Spectrum | | Predicted IR Spectrum | IR Ion Spectrum (Predicted IRIS Spectrum, Adduct: [M+H]+) | 2023-02-03 | FELIX lab | View Spectrum | | Predicted IR Spectrum | IR Ion Spectrum (Predicted IRIS Spectrum, Adduct: [M+Na]+) | 2023-02-03 | FELIX lab | View Spectrum |
|
|---|
| Biological Properties |
|---|
| Cellular Locations | - Cytoplasm
- Extracellular
- Mitochondria
|
|---|
| Biospecimen Locations | - Blood
- Breast Milk
- Cerebrospinal Fluid (CSF)
- Feces
- Saliva
- Sweat
- Urine
|
|---|
| Tissue Locations | - All Tissues
- Placenta
- Prostate
|
|---|
| Pathways | |
|---|
| Normal Concentrations |
|---|
| |
| Blood | Detected and Quantified | 92.71 ± 13.41 uM | Adult (>18 years old) | Both | Normal | | details | | Blood | Detected and Quantified | 30.00-400.0 uM | Adult (>18 years old) | Both | Normal | | details | | Blood | Detected and Quantified | 122.3(27.85) uM | Adult (>18 years old) | Both | Normal | | details | | Blood | Detected and Quantified | 40-160 uM | Not Specified | Not Specified | Normal | | details | | Blood | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | | Blood | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | | Blood | Detected and Quantified | 114.2 +/- 27 uM | Adult (>18 years old) | Both | Normal | | details | | Blood | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | | Blood | Detected and Quantified | 86.09 ± 39.35 uM | Adult (>18 years old) | Both | Normal | | details | | Blood | Detected and Quantified | 63.58 ± 32.23 uM | Adult (>18 years old) | Both | Normal | | details | | Blood | Detected and Quantified | 41.24 ± 13.27 uM | Adult (>18 years old) | Both | Normal | | details | | Blood | Detected and Quantified | 83.85 ± 10.91 uM | Adult (>18 years old) | Both | Normal | | details | | Blood | Detected and Quantified | 40.95 ± 27.74 uM | Adult (>18 years old) | Both | Normal | | details | | Blood | Detected and Quantified | 110.16 ± 16.93 uM | Adult (>18 years old) | Both | Normal | | details | | Blood | Detected and Quantified | 54.2 +/- 0.8 uM | Children (1-13 years old) | Both | Normal | | details | | Blood | Detected and Quantified | 190.0 (30.0-400.0) uM | Adult (>18 years old) | Both | Normal | | details | | Blood | Detected and Quantified | 122.0 +/- 30.0 uM | Children (1-13 years old) | Both | Normal | | details | | Blood | Detected and Quantified | 88.0 +/- 33.0 uM | Adult (>18 years old) | Both | Normal | | details | | Blood | Detected and Quantified | 95.94 ± 12.75 uM | Adult (>18 years old) | Both | Normal | | details | | Blood | Detected and Quantified | 29 ± 10.68 uM | Adult (>18 years old) | Both | Normal | | details | | Breast Milk | Detected and Quantified | 2700 +/- 680 uM | Adult (>18 years old) | Female | Normal | | details | | Cerebrospinal Fluid (CSF) | Detected and Quantified | 225 +/- 96 uM | Adult (>18 years old) | Both | Normal | | details | | Cerebrospinal Fluid (CSF) | Detected and Quantified | 176.0 +/- 50.0 uM | Adult (>18 years old) | Both | Normal | | details | | Cerebrospinal Fluid (CSF) | Detected and Quantified | 350.0 +/- 240.0 uM | Adult (>18 years old) | Not Specified | Normal | | details | | Cerebrospinal Fluid (CSF) | Detected and Quantified | 400.0 +/- 170.0 uM | Adult (>18 years old) | Not Specified | Normal | | details | | Cerebrospinal Fluid (CSF) | Detected and Quantified | 75-275 uM | Not Specified | Not Specified | Normal | | details | | Cerebrospinal Fluid (CSF) | Detected and Quantified | 370.0 (110.0 - 630.0) uM | Adult (>18 years old) | Both | Normal | | details | | Feces | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | | Feces | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | | Feces | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | | Feces | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | | Saliva | Detected and Quantified | 370 (3-66177) uM | Adult (>18 years old) | Male | Normal | | details | | Saliva | Detected and Quantified | 18.1 +/- 10.3 uM | Adult (>18 years old) | Female | Normal | | details | | Saliva | Detected and Quantified | 16.9 +/- 9.95 uM | Adult (>18 years old) | Female | Normal | | details | | Saliva | Detected and Quantified | 12.2 +/- 7.87 uM | Adult (>18 years old) | Female | Normal | | details | | Saliva | Detected and Quantified | 10.9 +/- 8.35 uM | Adult (>18 years old) | Male | Normal | | details | | Saliva | Detected and Quantified | 83.90 +/- 37.92 uM | Adult (>18 years old) | Female | Normal | | details | | Saliva | Detected and Quantified | 320 (15-4984) uM | Adult (>18 years old) | Female | Normal | | details | | Saliva | Detected and Quantified | 192 (10-1857) uM | Adult (>18 years old) | Male | Normal | | details | | Saliva | Detected and Quantified | 18 (1-338) uM | Adult (>18 years old) | Male | Normal | | details | | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Not Specified | Normal | | details | | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | | Saliva | Detected and Quantified | 28.50 +/- 9.89 uM | Adult (>18 years old) | Both | Normal | | details | | Saliva | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | | Saliva | Detected and Quantified | 1 - 4456 uM | Adult (>18 years old) | Male | normal | | details | | Sweat | Detected but not Quantified | Not Quantified | Adult | Both | Normal | | details | | Urine | Detected and Quantified | 422.9 +/- 246.8 umol/mmol creatinine | Newborn (0-30 days old) | Female | Normal | | details | | Urine | Detected and Quantified | 440 umol/mmol creatinine | Newborn (0-30 days old) | Both | Normal | | details | | Urine | Detected and Quantified | 39.6-893.5 umol/mmol creatinine | Newborn (0-30 days old) | Both | Normal | | details | | Urine | Detected and Quantified | 0-4.1 umol/mmol creatinine | Infant (0-1 year old) | Female | Normal | | details | | Urine | Detected and Quantified | 0-33.7 umol/mmol creatinine | Infant (0-1 year old) | Female | Normal | | details | | Urine | Detected and Quantified | 0-22.7 umol/mmol creatinine | Infant (0-1 year old) | Male | Normal | | details | | Urine | Detected and Quantified | 0-21.0 umol/mmol creatinine | Infant (0-1 year old) | Male | Normal | | details | | Urine | Detected and Quantified | 46-1400 umol/mmol creatinine | Newborn (0-30 days old) | Both | Normal | | details | | Urine | Detected and Quantified | 226.32 +/- 98.12 umol/mmol creatinine | Infant (0-1 year old) | Both | Normal | | details | | Urine | Detected and Quantified | 382.2 +/- 208.3 umol/mmol creatinine | Newborn (0-30 days old) | Male | Normal | | details | | Urine | Detected and Quantified | 242.0 +/- 129.6 umol/mmol creatinine | Adult (>18 years old) | Female | Normal | | details | | Urine | Detected and Quantified | 379.57 (228.21-614.87) umol/mmol creatinine | Newborn (0-30 days old) | Both | Normal | | details | | Urine | Detected and Quantified | 181.0 +/- 97.0 umol/mmol creatinine | Adult (>18 years old) | Male | Normal | | details | | Urine | Detected and Quantified | 184.2 (58.7-651.7) umol/mmol creatinine | Adolescent (13-18 years old) | Both | Normal | | details | | Urine | Detected and Quantified | 208.6 (33.2-445.1) umol/mmol creatinine | Children (1-13 years old) | Both | Normal | | details | | Urine | Detected and Quantified | 708.9 (25.2-3168.4) umol/mmol creatinine | Infant (0-1 year old) | Both | Normal | | details | | Urine | Detected and Quantified | 972.5 (89.5-1647.7) umol/mmol creatinine | Newborn (0-30 days old) | Both | Normal | | details | | Urine | Detected and Quantified | 280.6 +/- 115.2 umol/mmol creatinine | Adult (>18 years old) | Female | Normal | | details | | Urine | Detected and Quantified | 172.8 +/- 87.4 umol/mmol creatinine | Adult (>18 years old) | Male | Normal | | details | | Urine | Detected and Quantified | 300.0 umol/mmol creatinine | Adult (>18 years old) | Both | Normal | | details | | Urine | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | | Urine | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | | Urine | Detected and Quantified | 371(102-611) umol/mmol creatinine | Adult (>18 years old) | Both | Normal | | details | | Urine | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | | Urine | Detected and Quantified | 242.34 (81.79 – 403.84) umol/mmol creatinine | Adult (>18 years old) | Both | Normal | | details | | Urine | Detected and Quantified | 493.679 +/- 202.522 umol/mmol creatinine | Children (1 - 13 years old) | Not Specified | Normal | | details | | Urine | Detected and Quantified | <757.09 umol/mmol creatinine | Children (1 - 18 years old) | Both | Normal | | details | | Urine | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | | Urine | Detected and Quantified | 135-271 umol/mmol creatinine | Adult (>18 years old) | Female | Normal | | details | | Urine | Detected and Quantified | 137-210 umol/mmol creatinine | Adult (>18 years old) | Male | Normal | | details | | Urine | Detected and Quantified | 119.45 umol/mmol creatinine | Adult (>18 years old) | Male | Normal | | details | | Urine | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Male | Normal | | details | | Urine | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | | Urine | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | | Urine | Detected and Quantified | 203 (49-600) umol/mmol creatinine | Adult (>18 years old) | Both | Normal | | details | | Urine | Detected and Quantified | 440.6 umol/mmol creatinine | Adult (>18 years old) | Both | Normal | | details | | Urine | Detected and Quantified | 14.712-73.559 umol/mmol creatinine | Infant (0-1 year old) | Both | Normal | | details | | Urine | Detected and Quantified | 271.8 +/- 90.0 umol/mmol creatinine | Adult (>18 years old) | Both | Normal | | details | | Urine | Detected and Quantified | 155 (70-226) umol/mmol creatinine | Adult (>18 years old) | Both | Normal | | details | | Urine | Detected and Quantified | 46.87-484.31 umol/mmol creatinine | Adult (>18 years old) | Both | Normal | | details |
|
|---|
| Abnormal Concentrations |
|---|
| |
| Blood | Detected and Quantified | 51.9 (16.5) uM | Adult (>18 years old) | Female | Pregnancy | | details | | Blood | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Pancreatic cancer | | details | | Blood | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Oesophageal cancer | | details | | Blood | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Colorectal cancer | | details | | Blood | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Schizophrenia | | details | | Blood | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Schizophrenia | | details | | Blood | Detected and Quantified | 85.9 (19.1) uM | Adult (>18 years old) | Female | Early preeclampsia | | details | | Blood | Detected and Quantified | 79.3 (19.3) uM | Adult (>18 years old) | Female | Pregnancy | | details | | Blood | Detected and Quantified | 85.9 (26.9) uM | Adult (>18 years old) | Female | Late-onset preeclampsia | | details | | Blood | Detected and Quantified | 74.1 (23.5) uM | Adult (>18 years old) | Female | Pregnancy | | details | | Blood | Detected and Quantified | 57.2 (18.7) uM | Adult (>18 years old) | Female | Down syndrome pregnancy | | details | | Blood | Detected and Quantified | 77.6 +/- 19.1 uM | Adult (>18 years old) | Female | Pregnancy with fetuses with trisomy 18 | | details | | Blood | Detected and Quantified | 66.1 +/- 22.9 uM | Adult (>18 years old) | Female | Pregnancy | | details | | Blood | Detected and Quantified | 59.29 (11.58) uM | Adult (>18 years old) | Female | Pregnancy with fetus having congenital heart defect | | details | | Blood | Detected and Quantified | 61.85 (13.38) uM | Adult (>18 years old) | Female | Pregnancy | | details | | Blood | Detected and Quantified | 80.2 +/- 44.9 uM | Adult (>18 years old) | Both | Heart Transplant | | details | | Blood | Detected and Quantified | 144.54(44.65) uM | Adult (>18 years old) | Both | Heart failure with preserved ejection fraction | | details | | Blood | Detected and Quantified | 117.6 +/- 37.2 uM | Adult (>18 years old) | Both | Hyperoxalemia | | details | | Blood | Detected and Quantified | 141.3 +/- 54.7 uM | Adult (>18 years old) | Both | Hyperoxalemia | | details | | Blood | Detected and Quantified | 71-107 uM | Children (1-13 years old) | Both | 2-Ketoglutarate dehydrogenase complex deficiency | | details | | Cerebrospinal Fluid (CSF) | Detected and Quantified | 2400.0 uM | Adult (>18 years old) | Both | Canavan Disease | | details | | Cerebrospinal Fluid (CSF) | Detected and Quantified | 149.400-152.400 uM | Children (1-13 years old) | Both | 2-Ketoglutarate dehydrogenase complex deficiency | | details | | Feces | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Colorectal cancer | | details | | Feces | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Irritable Bowel Syndrome | | details | | Feces | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Colorectal cancer | | details | | Feces | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Ulcerative colitis | | details | | Feces | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Crohn disease | | details | | Feces | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Colorectal Cancer | | details | | Saliva | Detected and Quantified | 85.33 +/- 8.98 uM | Adult (>18 years old) | Both | Lewy body disease | | details | | Saliva | Detected and Quantified | 67.38 +/- 26.37 uM | Adult (>18 years old) | Male | Frontotemporal lobe dementia | | details | | Saliva | Detected and Quantified | 66.67 +/- 68.53 uM | Adult (>18 years old) | Male | Alzheimer's disease | | details | | Urine | Detected and Quantified | 181.5 +/- 5.7 umol/mmol creatinine | Adult (>18 years old) | Both | 3-Hydroxy-3- methylglutaryl-CoA lyase (HL) deficency | | details | | Urine | Detected and Quantified | 689.6 +/- 47.3 umol/mmol creatinine | Adult (>18 years old) | Both | Propionic acidemia | | details | | Urine | Detected and Quantified | 304.51 (105.96 – 586.60) umol/mmol creatinine | Adult (>18 years old) | Both | Type 1 diabetes Mellitus | | details | | Urine | Detected and Quantified | 154 umol/mmol creatinine | Adult (>18 years old) | Female | Rhabdomyolysis | | details | | Urine | Detected and Quantified | 17.35 umol/mmol creatinine | Children (1-13 years old) | Female | Primary Hypomagnesemia | | details | | Urine | Detected and Quantified | 268.0 (53.0-1111.0) umol/mmol creatinine | Not Specified | Both | Lung cancer | | details | | Urine | Detected and Quantified | 11.2 umol/mmol creatinine | Adult (>18 years old) | Both | Paraquat poisoning | | details | | Urine | Detected and Quantified | 1.177-354.851 umol/mmol creatinine | Infant (0-1 year old) | Both | Amish lethal microcephaly | | details | | Urine | Detected and Quantified | 998 umol/mmol creatinine | Newborn (0-30 days old) | Female | Deafness, Onychodystrophy, Osteodystrophy, Mental Retardation, and Seizures Syndrome | | details | | Urine | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Bladder cancer | | details | | Urine | Detected and Quantified | 191.7 +/- 4.1 umol/mmol creatinine | Adult (>18 years old) | Both | 3-Hydroxy-3- methylglutaryl-CoA lyase (HL) deficency | | details | | Urine | Detected and Quantified | 80.9 +/- 1.8 umol/mmol creatinine | Adult (>18 years old) | Both | Argininosuccinic aciduria (ASL) | | details | | Urine | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Colorectal cancer | | details | | Urine | Detected and Quantified | 712.3 +/- 82.8 umol/mmol creatinine | Adult (>18 years old) | Both | Propionic acidemia | | details | | Urine | Detected and Quantified | 457.6 +/- 17.5 umol/mmol creatinine | Adult (>18 years old) | Both | Tyrosinemia I | | details | | Urine | Detected and Quantified | 81.8 +/- 10.4 umol/mmol creatinine | Adult (>18 years old) | Both | Phenylketonuria | | details | | Urine | Detected and Quantified | 291.9 +/- 14.6 umol/mmol creatinine | Adult (>18 years old) | Both | Phenylketonuria | | details | | Urine | Detected and Quantified | 576.1 +/- 15.2 umol/mmol creatinine | Adult (>18 years old) | Both | Maple syrup urine disease | | details | | Urine | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Schizophrenia | | details | | Urine | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Normal | | details | | Urine | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Schizophrenia | | details | | Urine | Detected but not Quantified | Not Quantified | Adult (>18 years old) | Both | Colorectal cancer | | details | | Urine | Detected and Quantified | 478.296 +/- 354.079 umol/mmol creatinine | Children (1 - 13 years old) | Not Specified | Eosinophilic esophagitis | | details |
|
|---|
| Associated Disorders and Diseases |
|---|
| Disease References | | Hyperoxalemia |
|---|
- Ogawa Y, Machida N, Jahana M, Gakiya M, Chinen Y, Oda M, Morozumi M, Sugaya K: Major factors modulating the serum oxalic acid level in hemodialysis patients. Front Biosci. 2004 Sep 1;9:2901-8. [PubMed:15353324 ]
| | Late-onset preeclampsia |
|---|
- Bahado-Singh RO, Akolekar R, Mandal R, Dong E, Xia J, Kruger M, Wishart DS, Nicolaides K: First-trimester metabolomic detection of late-onset preeclampsia. Am J Obstet Gynecol. 2013 Jan;208(1):58.e1-7. doi: 10.1016/j.ajog.2012.11.003. Epub 2012 Nov 13. [PubMed:23159745 ]
| | Pregnancy |
|---|
- Bahado-Singh RO, Akolekar R, Mandal R, Dong E, Xia J, Kruger M, Wishart DS, Nicolaides K: Metabolomics and first-trimester prediction of early-onset preeclampsia. J Matern Fetal Neonatal Med. 2012 Oct;25(10):1840-7. doi: 10.3109/14767058.2012.680254. Epub 2012 Apr 28. [PubMed:22494326 ]
- Bahado-Singh RO, Akolekar R, Mandal R, Dong E, Xia J, Kruger M, Wishart DS, Nicolaides K: First-trimester metabolomic detection of late-onset preeclampsia. Am J Obstet Gynecol. 2013 Jan;208(1):58.e1-7. doi: 10.1016/j.ajog.2012.11.003. Epub 2012 Nov 13. [PubMed:23159745 ]
- Bahado-Singh RO, Akolekar R, Mandal R, Dong E, Xia J, Kruger M, Wishart DS, Nicolaides K: Metabolomic analysis for first-trimester Down syndrome prediction. Am J Obstet Gynecol. 2013 May;208(5):371.e1-8. doi: 10.1016/j.ajog.2012.12.035. Epub 2013 Jan 8. [PubMed:23313728 ]
- Bahado-Singh RO, Akolekar R, Chelliah A, Mandal R, Dong E, Kruger M, Wishart DS, Nicolaides K: Metabolomic analysis for first-trimester trisomy 18 detection. Am J Obstet Gynecol. 2013 Jul;209(1):65.e1-9. doi: 10.1016/j.ajog.2013.03.028. Epub 2013 Mar 25. [PubMed:23535240 ]
- Bahado-Singh RO, Ertl R, Mandal R, Bjorndahl TC, Syngelaki A, Han B, Dong E, Liu PB, Alpay-Savasan Z, Wishart DS, Nicolaides KH: Metabolomic prediction of fetal congenital heart defect in the first trimester. Am J Obstet Gynecol. 2014 Sep;211(3):240.e1-240.e14. doi: 10.1016/j.ajog.2014.03.056. Epub 2014 Apr 1. [PubMed:24704061 ]
| | Early preeclampsia |
|---|
- Bahado-Singh RO, Akolekar R, Mandal R, Dong E, Xia J, Kruger M, Wishart DS, Nicolaides K: Metabolomics and first-trimester prediction of early-onset preeclampsia. J Matern Fetal Neonatal Med. 2012 Oct;25(10):1840-7. doi: 10.3109/14767058.2012.680254. Epub 2012 Apr 28. [PubMed:22494326 ]
| | Schizophrenia |
|---|
- Yang J, Chen T, Sun L, Zhao Z, Qi X, Zhou K, Cao Y, Wang X, Qiu Y, Su M, Zhao A, Wang P, Yang P, Wu J, Feng G, He L, Jia W, Wan C: Potential metabolite markers of schizophrenia. Mol Psychiatry. 2013 Jan;18(1):67-78. doi: 10.1038/mp.2011.131. Epub 2011 Oct 25. [PubMed:22024767 ]
- Xuan J, Pan G, Qiu Y, Yang L, Su M, Liu Y, Chen J, Feng G, Fang Y, Jia W, Xing Q, He L: Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action. J Proteome Res. 2011 Dec 2;10(12):5433-43. doi: 10.1021/pr2006796. Epub 2011 Nov 8. [PubMed:22007635 ]
- Cai HL, Li HD, Yan XZ, Sun B, Zhang Q, Yan M, Zhang WY, Jiang P, Zhu RH, Liu YP, Fang PF, Xu P, Yuan HY, Zhang XH, Hu L, Yang W, Ye HS: Metabolomic analysis of biochemical changes in the plasma and urine of first-episode neuroleptic-naive schizophrenia patients after treatment with risperidone. J Proteome Res. 2012 Aug 3;11(8):4338-50. doi: 10.1021/pr300459d. Epub 2012 Jul 26. [PubMed:22800120 ]
| | Pancreatic cancer |
|---|
- Zhang L, Jin H, Guo X, Yang Z, Zhao L, Tang S, Mo P, Wu K, Nie Y, Pan Y, Fan D: Distinguishing pancreatic cancer from chronic pancreatitis and healthy individuals by (1)H nuclear magnetic resonance-based metabonomic profiles. Clin Biochem. 2012 Sep;45(13-14):1064-9. doi: 10.1016/j.clinbiochem.2012.05.012. Epub 2012 May 19. [PubMed:22613268 ]
| | Canavan disease |
|---|
- Wevers RA, Engelke U, Wendel U, de Jong JG, Gabreels FJ, Heerschap A: Standardized method for high-resolution 1H-NMR of cerebrospinal fluid. Clin Chem. 1995 May;41(5):744-51. [PubMed:7729054 ]
| | 2-Ketoglutarate dehydrogenase complex deficiency |
|---|
- Kohlschutter A, Behbehani A, Langenbeck U, Albani M, Heidemann P, Hoffmann G, Kleineke J, Lehnert W, Wendel U: A familial progressive neurodegenerative disease with 2-oxoglutaric aciduria. Eur J Pediatr. 1982 Feb;138(1):32-7. [PubMed:7075624 ]
| | Ulcerative colitis |
|---|
- Azario I, Pievani A, Del Priore F, Antolini L, Santi L, Corsi A, Cardinale L, Sawamoto K, Kubaski F, Gentner B, Bernardo ME, Valsecchi MG, Riminucci M, Tomatsu S, Aiuti A, Biondi A, Serafini M: Neonatal umbilical cord blood transplantation halts skeletal disease progression in the murine model of MPS-I. Sci Rep. 2017 Aug 25;7(1):9473. doi: 10.1038/s41598-017-09958-9. [PubMed:28842642 ]
| | Crohn's disease |
|---|
- Azario I, Pievani A, Del Priore F, Antolini L, Santi L, Corsi A, Cardinale L, Sawamoto K, Kubaski F, Gentner B, Bernardo ME, Valsecchi MG, Riminucci M, Tomatsu S, Aiuti A, Biondi A, Serafini M: Neonatal umbilical cord blood transplantation halts skeletal disease progression in the murine model of MPS-I. Sci Rep. 2017 Aug 25;7(1):9473. doi: 10.1038/s41598-017-09958-9. [PubMed:28842642 ]
| | Irritable bowel syndrome |
|---|
- Hong YS, Hong KS, Park MH, Ahn YT, Lee JH, Huh CS, Lee J, Kim IK, Hwang GS, Kim JS: Metabonomic understanding of probiotic effects in humans with irritable bowel syndrome. J Clin Gastroenterol. 2011 May-Jun;45(5):415-25. doi: 10.1097/MCG.0b013e318207f76c. [PubMed:21494186 ]
| | Frontotemporal dementia |
|---|
- Tsuruoka M, Hara J, Hirayama A, Sugimoto M, Soga T, Shankle WR, Tomita M: Capillary electrophoresis-mass spectrometry-based metabolome analysis of serum and saliva from neurodegenerative dementia patients. Electrophoresis. 2013 Oct;34(19):2865-72. doi: 10.1002/elps.201300019. Epub 2013 Sep 6. [PubMed:23857558 ]
| | Lewy body disease |
|---|
- Tsuruoka M, Hara J, Hirayama A, Sugimoto M, Soga T, Shankle WR, Tomita M: Capillary electrophoresis-mass spectrometry-based metabolome analysis of serum and saliva from neurodegenerative dementia patients. Electrophoresis. 2013 Oct;34(19):2865-72. doi: 10.1002/elps.201300019. Epub 2013 Sep 6. [PubMed:23857558 ]
| | Alzheimer's disease |
|---|
- Tsuruoka M, Hara J, Hirayama A, Sugimoto M, Soga T, Shankle WR, Tomita M: Capillary electrophoresis-mass spectrometry-based metabolome analysis of serum and saliva from neurodegenerative dementia patients. Electrophoresis. 2013 Oct;34(19):2865-72. doi: 10.1002/elps.201300019. Epub 2013 Sep 6. [PubMed:23857558 ]
| | Paraquat poisoning |
|---|
- Bairaktari E, Katopodis K, Siamopoulos KC, Tsolas O: Paraquat-induced renal injury studied by 1H nuclear magnetic resonance spectroscopy of urine. Clin Chem. 1998 Jun;44(6 Pt 1):1256-61. [PubMed:9625050 ]
| | Lung Cancer |
|---|
- Wishart DS, Knox C, Guo AC, Eisner R, Young N, Gautam B, Hau DD, Psychogios N, Dong E, Bouatra S, Mandal R, Sinelnikov I, Xia J, Jia L, Cruz JA, Lim E, Sobsey CA, Shrivastava S, Huang P, Liu P, Fang L, Peng J, Fradette R, Cheng D, Tzur D, Clements M, Lewis A, De Souza A, Zuniga A, Dawe M, Xiong Y, Clive D, Greiner R, Nazyrova A, Shaykhutdinov R, Li L, Vogel HJ, Forsythe I: HMDB: a knowledgebase for the human metabolome. Nucleic Acids Res. 2009 Jan;37(Database issue):D603-10. doi: 10.1093/nar/gkn810. Epub 2008 Oct 25. [PubMed:18953024 ]
| | Deafness, Onychodystrophy, Osteodystrophy, Mental Retardation, and Seizures Syndrome |
|---|
- James AW, Miranda SG, Culver K, Hall BD, Golabi M: DOOR syndrome: clinical report, literature review and discussion of natural history. Am J Med Genet A. 2007 Dec 1;143A(23):2821-31. doi: 10.1002/ajmg.a.32054. [PubMed:17994565 ]
| | Amish lethal microcephaly |
|---|
- Kelley RI, Robinson D, Puffenberger EG, Strauss KA, Morton DH: Amish lethal microcephaly: a new metabolic disorder with severe congenital microcephaly and 2-ketoglutaric aciduria. Am J Med Genet. 2002 Nov 1;112(4):318-26. doi: 10.1002/ajmg.10529. [PubMed:12376931 ]
| | Rhabdomyolysis |
|---|
- Bairaktari E, Seferiadis K, Liamis G, Psihogios N, Tsolas O, Elisaf M: Rhabdomyolysis-related renal tubular damage studied by proton nuclear magnetic resonance spectroscopy of urine. Clin Chem. 2002 Jul;48(7):1106-9. [PubMed:12089184 ]
| | Primary hypomagnesemia |
|---|
- Kari JA, Farouq M, Alshaya HO: Familial hypomagnesemia with hypercalciuria and nephrocalcinosis. Pediatr Nephrol. 2003 Jun;18(6):506-10. Epub 2003 Apr 29. [PubMed:12720080 ]
| | Diabetes mellitus type 1 |
|---|
- (). Lorena Ivona ŞTEFAN, Alina NICOLESCU, Simona POPA, Maria MOŢA, Eugenia KOVACS and Calin DELEANU. 1H-NMR URINE METABOLIC PROFILING IN TYPE 1 DIABETES MELLITUS. Rev. Roum. Chim., 2010, 55(11-12), 1033-1037 . .
| | Argininosuccinic aciduria |
|---|
- Gronwald W, Klein MS, Kaspar H, Fagerer SR, Nurnberger N, Dettmer K, Bertsch T, Oefner PJ: Urinary metabolite quantification employing 2D NMR spectroscopy. Anal Chem. 2008 Dec 1;80(23):9288-97. doi: 10.1021/ac801627c. [PubMed:19551947 ]
| | Propionic acidemia |
|---|
- Gronwald W, Klein MS, Kaspar H, Fagerer SR, Nurnberger N, Dettmer K, Bertsch T, Oefner PJ: Urinary metabolite quantification employing 2D NMR spectroscopy. Anal Chem. 2008 Dec 1;80(23):9288-97. doi: 10.1021/ac801627c. [PubMed:19551947 ]
| | Tyrosinemia I |
|---|
- Gronwald W, Klein MS, Kaspar H, Fagerer SR, Nurnberger N, Dettmer K, Bertsch T, Oefner PJ: Urinary metabolite quantification employing 2D NMR spectroscopy. Anal Chem. 2008 Dec 1;80(23):9288-97. doi: 10.1021/ac801627c. [PubMed:19551947 ]
| | Phenylketonuria |
|---|
- Gronwald W, Klein MS, Kaspar H, Fagerer SR, Nurnberger N, Dettmer K, Bertsch T, Oefner PJ: Urinary metabolite quantification employing 2D NMR spectroscopy. Anal Chem. 2008 Dec 1;80(23):9288-97. doi: 10.1021/ac801627c. [PubMed:19551947 ]
| | Maple syrup urine disease |
|---|
- Gronwald W, Klein MS, Kaspar H, Fagerer SR, Nurnberger N, Dettmer K, Bertsch T, Oefner PJ: Urinary metabolite quantification employing 2D NMR spectroscopy. Anal Chem. 2008 Dec 1;80(23):9288-97. doi: 10.1021/ac801627c. [PubMed:19551947 ]
| | Colorectal cancer |
|---|
- Cheng Y, Xie G, Chen T, Qiu Y, Zou X, Zheng M, Tan B, Feng B, Dong T, He P, Zhao L, Zhao A, Xu LX, Zhang Y, Jia W: Distinct urinary metabolic profile of human colorectal cancer. J Proteome Res. 2012 Feb 3;11(2):1354-63. doi: 10.1021/pr201001a. Epub 2011 Dec 28. [PubMed:22148915 ]
- Ni Y, Xie G, Jia W: Metabonomics of human colorectal cancer: new approaches for early diagnosis and biomarker discovery. J Proteome Res. 2014 Sep 5;13(9):3857-70. doi: 10.1021/pr500443c. Epub 2014 Aug 14. [PubMed:25105552 ]
- Brown DG, Rao S, Weir TL, O'Malia J, Bazan M, Brown RJ, Ryan EP: Metabolomics and metabolic pathway networks from human colorectal cancers, adjacent mucosa, and stool. Cancer Metab. 2016 Jun 6;4:11. doi: 10.1186/s40170-016-0151-y. eCollection 2016. [PubMed:27275383 ]
- Sinha R, Ahn J, Sampson JN, Shi J, Yu G, Xiong X, Hayes RB, Goedert JJ: Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations. PLoS One. 2016 Mar 25;11(3):e0152126. doi: 10.1371/journal.pone.0152126. eCollection 2016. [PubMed:27015276 ]
- Goedert JJ, Sampson JN, Moore SC, Xiao Q, Xiong X, Hayes RB, Ahn J, Shi J, Sinha R: Fecal metabolomics: assay performance and association with colorectal cancer. Carcinogenesis. 2014 Sep;35(9):2089-96. doi: 10.1093/carcin/bgu131. Epub 2014 Jul 18. [PubMed:25037050 ]
| | Eosinophilic esophagitis |
|---|
- Slae, M., Huynh, H., Wishart, D.S. (2014). Analysis of 30 normal pediatric urine samples via NMR spectroscopy (unpublished work). NA.
|
|
|---|
| Associated OMIM IDs | - 181500 (Schizophrenia)
- 260350 (Pancreatic cancer)
- 203740 (2-Ketoglutarate dehydrogenase complex deficiency)
- 271900 (Canavan disease)
- 266600 (Crohn's disease)
- 600274 (Frontotemporal dementia)
- 104300 (Alzheimer's disease)
- 248600 (Maple syrup urine disease)
- 261600 (Phenylketonuria)
- 276700 (Tyrosinemia I)
- 610247 (Eosinophilic esophagitis)
- 114500 (Colorectal cancer)
- 606054 (Propionic acidemia)
- 207900 (Argininosuccinic aciduria)
- 248250 (Primary hypomagnesemia)
- 222100 (Diabetes mellitus type 1)
- 607196 (Amish lethal microcephaly)
- 220500 (Deafness, Onychodystrophy, Osteodystrophy, Mental Retardation, and Seizures Syndrome)
- 211980 (Lung Cancer)
|
|---|
| External Links |
|---|
| DrugBank ID | DB04272 |
|---|
| Phenol Explorer Compound ID | Not Available |
|---|
| FooDB ID | FDB030735 |
|---|
| KNApSAcK ID | C00007619 |
|---|
| Chemspider ID | 305 |
|---|
| KEGG Compound ID | C00158 |
|---|
| BioCyc ID | CIT |
|---|
| BiGG ID | 34080 |
|---|
| Wikipedia Link | Citric_Acid |
|---|
| METLIN ID | 124 |
|---|
| PubChem Compound | 311 |
|---|
| PDB ID | Not Available |
|---|
| ChEBI ID | 30769 |
|---|
| Food Biomarker Ontology | Not Available |
|---|
| VMH ID | CIT |
|---|
| MarkerDB ID | MDB00000049 |
|---|
| Good Scents ID | Not Available |
|---|
| References |
|---|
| Synthesis Reference | Evans, D. W. S. Hydrolysis of ethyl methylenecitrate [5,5-bis(ethoxycarbonylmethyl)-1,3-dioxolan-4-one] and an attempted synthesis of agaric acid. Journal of the Chemical Society (1959), 1313-14. |
|---|
| Material Safety Data Sheet (MSDS) | Download (PDF) |
|---|
| General References | - Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009 Feb 12;457(7231):910-4. doi: 10.1038/nature07762. [PubMed:19212411 ]
- Hoffmann GF, Meier-Augenstein W, Stockler S, Surtees R, Rating D, Nyhan WL: Physiology and pathophysiology of organic acids in cerebrospinal fluid. J Inherit Metab Dis. 1993;16(4):648-69. [PubMed:8412012 ]
- Commodari F, Arnold DL, Sanctuary BC, Shoubridge EA: 1H NMR characterization of normal human cerebrospinal fluid and the detection of methylmalonic acid in a vitamin B12 deficient patient. NMR Biomed. 1991 Aug;4(4):192-200. [PubMed:1931558 ]
- Moreno AJ, Brown JM, Salinas JA, Feaster BL 3rd, Brown TJ: Ga-67 positivity in sarcoidosis of the skin with coincident thyroid uptake of uncertain etiology. Clin Nucl Med. 1984 Mar;9(3):165-6. [PubMed:6705419 ]
- Wenk J, Foitzik A, Achterberg V, Sabiwalsky A, Dissemond J, Meewes C, Reitz A, Brenneisen P, Wlaschek M, Meyer-Ingold W, Scharffetter-Kochanek K: Selective pick-up of increased iron by deferoxamine-coupled cellulose abrogates the iron-driven induction of matrix-degrading metalloproteinase 1 and lipid peroxidation in human dermal fibroblasts in vitro: a new dressing concept. J Invest Dermatol. 2001 Jun;116(6):833-9. [PubMed:11407968 ]
- Wei R, Han JJ, Bai B, Ren DL, Chen B, Yang MF, Xia ZL: Analysis of factors influencing the blood levels and activities of tissue-type plasminogen activator (t-PA). Clin Hemorheol Microcirc. 2003;29(3-4):351-6. [PubMed:14724361 ]
- McBane RD 2nd, Karnicki K, Tahirkheli N, Miller RS, Owen WG: Platelet characteristics associated with coronary artery disease. J Thromb Haemost. 2003 Jun;1(6):1296-303. [PubMed:12871333 ]
- Jurasovic J, Cvitkovic P, Pizent A, Colak B, Telisman S: Semen quality and reproductive endocrine function with regard to blood cadmium in Croatian male subjects. Biometals. 2004 Dec;17(6):735-43. [PubMed:15689116 ]
- Mairiang E, Hanpanich P, Sriboonlue P: In vivo 31P-MRS assessment of muscle-pH, cytolsolic-[Mg2+] and phosphorylation potential after supplementing hypokaliuric renal stone patients with potassium and magnesium salts. Magn Reson Imaging. 2004 Jun;22(5):715-9. [PubMed:15172066 ]
- Tammen H, Schulte I, Hess R, Menzel C, Kellmann M, Mohring T, Schulz-Knappe P: Peptidomic analysis of human blood specimens: comparison between plasma specimens and serum by differential peptide display. Proteomics. 2005 Aug;5(13):3414-22. [PubMed:16038021 ]
- Chiueh CC, Andoh T, Lai AR, Lai E, Krishna G: Neuroprotective strategies in Parkinson's disease: protection against progressive nigral damage induced by free radicals. Neurotox Res. 2000;2(2-3):293-310. [PubMed:16787846 ]
- Batchelor WB, Tolleson TR, Huang Y, Larsen RL, Mantell RM, Dillard P, Davidian M, Zhang D, Cantor WJ, Sketch MH Jr, Ohman EM, Zidar JP, Gretler D, DiBattiste PM, Tcheng JE, Califf RM, Harrington RA: Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide. Circulation. 2002 Sep 17;106(12):1470-6. [PubMed:12234950 ]
- A J, Trygg J, Gullberg J, Johansson AI, Jonsson P, Antti H, Marklund SL, Moritz T: Extraction and GC/MS analysis of the human blood plasma metabolome. Anal Chem. 2005 Dec 15;77(24):8086-94. [PubMed:16351159 ]
- Bairaktari E, Katopodis K, Siamopoulos KC, Tsolas O: Paraquat-induced renal injury studied by 1H nuclear magnetic resonance spectroscopy of urine. Clin Chem. 1998 Jun;44(6 Pt 1):1256-61. [PubMed:9625050 ]
- Wan KW, Malgesini B, Verpilio I, Ferruti P, Griffiths PC, Paul A, Hann AC, Duncan R: Poly(amidoamine) salt form: effect on pH-dependent membrane activity and polymer conformation in solution. Biomacromolecules. 2004 May-Jun;5(3):1102-9. [PubMed:15132705 ]
- Solheim BG, Flesland O, Brosstad F, Mollnes TE, Seghatchian J: Improved preservation of coagulation factors after pre-storage leukocyte depletion of whole blood. Transfus Apher Sci. 2003 Oct;29(2):133-9. [PubMed:12941351 ]
- Seiffert D, Thomas BE, Bradley JD, Munzer DA, Tchinnes MA, Kornhauser DM, Cain VA, Hua TA, Feuerstein GZ, Martin DE, Stern AM: Effects of the glycoprotein IIb/IIIa antagonist Roxifiban on P-selectin expression, fibrinogen binding, and microaggregate formation in a phase I dose-finding study: no evidence for platelet activation during treatment with a glycoprotein IIb/IIIa antagonist. Platelets. 2003 May;14(3):179-87. [PubMed:12850842 ]
- Odvina CV, Mason RP, Pak CY: Prevention of thiazide-induced hypokalemia without magnesium depletion by potassium-magnesium-citrate. Am J Ther. 2006 Mar-Apr;13(2):101-8. [PubMed:16645424 ]
- Wevers RA, Engelke U, Wendel U, de Jong JG, Gabreels FJ, Heerschap A: Standardized method for high-resolution 1H-NMR of cerebrospinal fluid. Clin Chem. 1995 May;41(5):744-51. [PubMed:7729054 ]
- McBane RD 2nd, Karnicki K, Miller RS, Owen WG: The impact of peripheral arterial disease on circulating platelets. Thromb Res. 2004;113(2):137-45. [PubMed:15115669 ]
- Abe T, Kobata H, Hanba Y, Kitabata Y, Narukawa N, Hasegawa H, Abe T, Fukagawa M: Study of plasma exchange for liver failure: beneficial and harmful effects. Ther Apher Dial. 2004 Jun;8(3):180-4. [PubMed:15154867 ]
- Caudarella R, Vescini F, Buffa A, Stefoni S: Citrate and mineral metabolism: kidney stones and bone disease. Front Biosci. 2003 Sep 1;8:s1084-106. [PubMed:12957820 ]
- Costello LC, Franklin RB: Testosterone and prolactin regulation of metabolic genes and citrate metabolism of prostate epithelial cells. Horm Metab Res. 2002 Aug;34(8):417-24. [PubMed:12198595 ]
- Elshenawy S, Pinney SE, Stuart T, Doulias PT, Zura G, Parry S, Elovitz MA, Bennett MJ, Bansal A, Strauss JF 3rd, Ischiropoulos H, Simmons RA: The Metabolomic Signature of the Placenta in Spontaneous Preterm Birth. Int J Mol Sci. 2020 Feb 4;21(3). pii: ijms21031043. doi: 10.3390/ijms21031043. [PubMed:32033212 ]
- Hu YY, Rawal A, Schmidt-Rohr K: Strongly bound citrate stabilizes the apatite nanocrystals in bone. Proc Natl Acad Sci U S A. 2010 Dec 28;107(52):22425-9. doi: 10.1073/pnas.1009219107. Epub 2010 Dec 2. [PubMed:21127269 ]
|
|---|